PEPG
PEPGStock
OFF
Close before Sep 10 scan
$3.15
Indicators

Loading indicators…

Sentiment Sources
StockTwits
News (Finnhub)
Sources: StockTwits, Finnhub+VADER
Split Clock
CROWD
WIRE
STREET
TAPE
Smart Money

PepGen Inc. (PEPG) Stock Analysis

A live, multi-source view of PepGen Inc. (PEPG): real-time price, technical indicators, Wall Street analyst consensus, recent news sentiment and social buzz — aggregated into one place so you can size up the stock at a glance.

About PepGen Inc.

PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1. It is also involved in FREEDOM-OLE, an open label expansion study. The company was founded in 2018 and is based in Boston, Massachusetts.

Sector: Healthcare · Industry: Biotechnology · United States · 57 employees · pepgen.com

Key statistics · as of 2026-09-06

As of 2026-09-06, PepGen Inc. (PEPG) had a market capitalization of $215.1M (forward -3.0) and a beta of 1.97; the shares traded in a 52-week range of $1.31 – $7.80 (108.7% over the year).

Market cap
$215.1M
Enterprise value
$114.3M
Forward P/E
-3.0
Price / book
1.80
EPS (trailing)
$-1.00
EPS (forward)
$-1.04
Payout ratio
0.0%
52-week range
$1.31 – $7.80
52-week change
108.7%
Beta
1.97
Average volume
917,376
Shares outstanding
69.2M
Short % of float
8.95%
Profit margin
0.0%

Fundamental figures are recorded once every few days, dated above; they are not live and can differ from the interactive tiles.

Last universe scan · 2026-09-10

In RapidTradeView’s 2026-09-10 scan of the US universe, PepGen Inc. (PEPG) last closed at $3.15 (the last completed close before that scan).

Technicals at the scan: RSI 60 (neutral territory), price +1.6% versus its 20-day average, 20-day versus 50-day average spread +23.0%, MACD histogram -0.04.

Sentiment inputs: StockTwits 100% bullish; analyst consensus score 66/100.

Next scheduled company event: in 62 days from the scan date.

Scan values are recorded once per trading day and are not live quotes; the interactive tiles above update in real time.

Smart Money · last 90 days

RapidTradeView has recorded no Congress or insider filing for PEPG in the last 90 days. Coverage of House, Senate and SEC Form 4 filings began in July 2026, and insider sells are tracked for universe tickers only, so this is our record, not a guarantee that nothing was filed. Who is trading what

RapidTradeView pick record

PEPG has not appeared in the daily picks yet. Full scoreboard

What this page covers

RapidTradeView pulls PepGen Inc. (PEPG) data from multiple independent sources and combines it into a single dashboard. Below the summary you’ll find live, interactive tiles for each of the following:

  • Price & chart — real-time quote with pre/post-market moves and a line or candlestick chart.
  • Technical indicators — RSI, MACD, moving averages, Bollinger Bands, volume and support/resistance, distilled into one overall signal.
  • Analyst consensus — the buy/hold/sell breakdown and price targets published by Wall Street analysts.
  • News sentiment — recent headlines, each scored for tone so the prevailing narrative is obvious.
  • Earnings — current EPS, year-over-year change and the next scheduled earnings date.
  • Social buzz — Reddit mention volume and StockTwits sentiment for the retail-trader angle.

How to read the signals

No single indicator tells the whole story. A bullish technical reading paired with a cautious analyst consensus, or strong social buzz against weak earnings, is exactly the kind of tension this view is built to surface. RapidTradeView’s signals are generated by deterministic, statistical models — they describe what the data is doing, they are not personalised recommendations to buy or sell PEPG.

Disclaimer: RapidTradeView is an educational sentiment-aggregation tool, not a licensed financial adviser, broker, or dealer. Nothing here is financial, investment, tax, or legal advice. Markets are risky and you can lose money. Always do your own research and consult a qualified professional before making any investment decision.